Luke Burkett Fondren, DO | |
1613 N Mckenzie St, Foley, AL 36535-2247 | |
(251) 949-3400 | |
Not Available |
Full Name | Luke Burkett Fondren |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 1613 N Mckenzie St, Foley, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255837886 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | DO.2036 (Alabama) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Luke Burkett Fondren, DO 7856 Westside Park Dr Ste H, Mobile, AL 36695-8539 Ph: (251) 450-8151 | Luke Burkett Fondren, DO 1613 N Mckenzie St, Foley, AL 36535-2247 Ph: (251) 949-3400 |
News Archive
Regulators, manufacturers and academic researchers from around the world will convene for a two-day workshop on the scientific and regulatory challenges posed by the use of probiotic ingredients in food products. Discussions will focus on how public standards can assist in supporting transparency, consistency and competitiveness of ethical industry players as health claims surrounding probiotic products undergo increased scrutiny.
Illustrating a commitment to the support of underrepresented minority researchers, the American Gastroenterological Association Research Foundation has announced the inaugural AGA Investing in the Future Student Research Fellowship Award recipients.
As concerns mount over whether there will be enough physicians to meet the nation's growing demand for health care, the number of osteopathic physicians (DOs) is reaching new heights, according to a report released today from the American Osteopathic Association.
Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.
› Verified 9 days ago